About this Journal Submit a Manuscript Table of Contents
Advances in Pharmacological Sciences
Volume 2012 (2012), Article ID 134523, 10 pages
http://dx.doi.org/10.1155/2012/134523
Review Article

An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists

1Phase I Unit of Clinical Pharmacological Research Center, Peking Union Medical College Hospital, 100032 Beijing, China
2Centre for Human Drug Research, 2333 CL Leiden, The Netherlands

Received 9 July 2011; Revised 2 December 2011; Accepted 7 December 2011

Academic Editor: Keith Wafford

Copyright © 2012 Xia Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. E. P. Seligman, E. F. Walker, and D. L. Rosenhan, Abnormal Psychology, W.W. Norton & Company, New York, NY, USA, 4th edition, 2000.
  2. A. S. Eison and U. L. Mullins, “Regulation of central 5-HT2A receptors: a review of in vivo studies,” Behavioural Brain Research, vol. 73, no. 1-2, pp. 177–181, 1995. View at Scopus
  3. G. Wong and P. Skolnick, “High affinity ligands for “diazepam-insensitive” benzodiazepines receptors,” European Journal of Pharmacology—Molecular Pharmacology Section, vol. 225, no. 1, pp. 63–68, 1992. View at Publisher · View at Google Scholar · View at Scopus
  4. J. R. Atack, “Subtype-selective GABAA receptor modulation yields a novel pharmacological profile: the design and development of TPA023,” Advances in Pharmacology, vol. 57, pp. 137–185, 2009. View at Scopus
  5. R. M. McKernan, T. W. Rosahl, D. S. Reynolds et al., “Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype,” Nature Neuroscience, vol. 3, no. 6, pp. 587–592, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. J. K. Rowlett, D. M. Platt, S. Lelas, J. R. Atack, and G. R. Dawson, “Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 3, pp. 915–920, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. Knabl, R. Witschi, K. Hösl et al., “Reversal of pathological pain through specific spinal GABAA receptor subtypes,” Nature, vol. 451, no. 7176, pp. 330–334, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. Knabl, U. B. Zeilhofer, F. Crestani, U. Rudolph, and H. U. Zeilhofer, “Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice,” Pain, vol. 141, no. 3, pp. 233–238, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. R. Atack, P. J. Bayley, G. R. Seabrook, K. A. Wafford, R. M. McKernan, and G. R. Dawson, “L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for α5-containing GABAA receptors,” Neuropharmacology, vol. 51, no. 6, pp. 1023–1029, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. T. M. Ballard, F. Knoflach, E. Prinssen et al., “RO4938581, a novel cognitive enhancer acting at GABAA α5 subunit-containing receptors,” Psychopharmacology, vol. 202, no. 1–3, pp. 207–223, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. J. De Visser, J. P. Van Der Post, P. P. De Waal, F. Cornet, A. F. Cohen, and J. M. A. Van Gerven, “Biomarkers for the effects of benzodiazepines in healthy volunteers,” British Journal of Clinical Pharmacology, vol. 55, no. 1, pp. 39–50, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. S. L. De Haas, S. J. De Visser, J. P. Van Der Post et al., “Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAAα2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers,” Journal of Psychopharmacology, vol. 21, no. 4, pp. 374–383, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. S. L. De Haas, S. J. De Visser, J. P. Van Der Post et al., “Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAAα2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers,” Journal of Psychopharmacology, vol. 22, no. 1, pp. 24–32, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. S. L. De Haas, K. L. Franson, J. A. J. Schmitt et al., “The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABAA 2,3 selective agonist, in comparison with lorazepam in healthy volunteers,” Journal of Psychopharmacology, vol. 23, no. 6, pp. 625–632, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. S. L. De Haas, R. C. Schoemaker, J. M. A. Van Gerven, P. Hoever, A. F. Cohen, and J. Dingemanse, “Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects,” Journal of Psychopharmacology, vol. 24, no. 11, pp. 1619–1629, 2010. View at Publisher · View at Google Scholar · View at PubMed
  16. A. L. Van Steveninck, B. N. M. Van Berckel, R. C. Schoemaker, D. D. Breimer, J. M. A. Van Gerven, and A. F. Cohen, “The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation,” Journal of Psychopharmacology, vol. 13, no. 1, pp. 10–17, 1999.
  17. J. M. P. Baas, N. Mol, J. L. Kenemans et al., “Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine,” Psychopharmacology, vol. 205, no. 1, pp. 73–84, 2009. View at Publisher · View at Google Scholar · View at PubMed
  18. A. L. Van Steveninck, S. Verver, H. C. Schoemaker et al., “Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers,” Clinical Pharmacology and Therapeutics, vol. 52, no. 4, pp. 402–408, 1992.
  19. A. L. Van Steveninck, H. C. Schoemaker, M. S. M. Pieters, R. Kroon, D. D. Breimer, and A. F. Cohen, “A comparison of the sensitivities of adaptive tracking, eye movement analysis, and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers,” Clinical Pharmacology and Therapeutics, vol. 50, no. 2, pp. 172–180, 1991.
  20. P. R. M. Bittencourt, P. Wade, A. T. Smith, and A. Richens, “The relationship between peak velocity of saccadic eye movements and serum benzodiazepine concentration,” British Journal of Clinical Pharmacology, vol. 12, no. 4, pp. 523–533, 1981.
  21. R. W. Baloh, A. W. Sills, W. E. Kumley, and V. Honrubia, “Quantitative measurement of saccade amplitude duration, and velocity,” Neurology, vol. 25, no. 11, pp. 1065–1070, 1975.
  22. H. Norris, “The action of sedatives on brain stem oculomotor systems in man,” Neuropharmacology, vol. 10, no. 2, pp. 181–191, 1971.
  23. A. Bond and M. Lader, “The use of analogue scales in rating subjective feelings,” British Journal of Medical Psychology, vol. 47, pp. 211–218, 1974.
  24. A. L. Van Steveninck, R. Gieschke, H. C. Schoemaker et al., “Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state,” Psychopharmacology, vol. 110, no. 4, pp. 471–478, 1993. View at Scopus
  25. A. L. Van Steveninck, A. E. Wallnöfer, R. C. Schoemaker et al., “A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population,” British Journal of Clinical Pharmacology, vol. 44, no. 3, pp. 267–275, 1997.
  26. J. R. Atack, K. A. Wafford, S. J. Tye et al., “TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3- (2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for α2- and 3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates,” Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 1, pp. 410–422, 2006. View at Publisher · View at Google Scholar · View at PubMed
  27. R. G. Borland and A. N. Nicholson, “Visual motor co-ordination and dynamic visual acuity,” British Journal of Clinical Pharmacology, vol. 18, no. 1, pp. 69S–72S, 1984.
  28. G. Griebel, G. Perrault, J. Simiand et al., “SL651498: an anxioselective compound with functional selectivity for α2- and α3-containing γ-aminobutyric acidA (GABAA) receptors,” Journal of Pharmacology and Experimental Therapeutics, vol. 298, no. 2, pp. 753–768, 2001.
  29. F. Crestani, J. R. Martin, H. Möhler, and U. Rudolph, “Mechanism of action of the hypnotic zolpidem in vivo,” British Journal of Pharmacology, vol. 131, no. 7, pp. 1251–1254, 2000.
  30. E. Sanna, F. Busonero, G. Talani et al., “Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes,” European Journal of Pharmacology, vol. 451, no. 2, pp. 103–110, 2002. View at Publisher · View at Google Scholar